cached image
We are testing a new system for linking grants to scientists.
The funding information displayed below comes from the
NIH Research Portfolio Online Reporting Tools and the
NSF Award Database.
The grant data on this page is limited to grants awarded in the United States and is thus partial. It can nonetheless be used to understand how funding patterns influence mentorship networks and vice-versa, which has deep implications on how research is done.
You can help! If you notice any innacuracies, please
sign in and mark grants as correct or incorrect matches.
Sign in to see low-probability grants and correct any errors in linkage between grants and researchers.
High-probability grants
According to our matching algorithm, Paul C. Zamecnik is the likely recipient of the following grants.
| Years |
Recipients |
Code |
Title / Keywords |
Matching
score |
| 1998 |
Zamecnik, Paul Charles |
R43Activity Code Description:
To support projects, limited in time and amount, to establish the technical merit and feasibility of R&D ideas which may ultimately lead to a commercial product(s) or service(s). |
Antisense Oligonucleotides Aganist Malaria in Vivo
The objective of this proposal is to initiate in vivo studies examining use of antisense oligonucleotides (AS ODNs) as chemotherapeutic agents to control/prevent malarial infection. This disease afflicts over 200 million people world wide, and is becoming increasingly difficult to treat due to wide spread resistance to currently available anti malarial drugs. New anti malarial compounds are urgently needed. AS ODNs work by specifically inhibiting gene expression of the target protein. We have shown that AS ODNs directed against several different genes in the malarial parasite Plasmodium falciparum can inhibit growth in in vitro culture, and now seek to examine the efficacy of such compounds in vivo. Because P. falciparum infects only humans or some species of monkeys, our initial studies will utilize small animal model systems consisting of the non-human malarial species P. gallinaceum and P. berghei. Studies will examine the effects of dose, frequency and route of administration in controlling infection. Establishing efficacy in these systems will provide the basis for future studies on the human parasite in monkeys, which in turn will lead to human clinical trials. PROPOSED COMMERCIAL APPLICATIONS: The world wide market for anti malarials is estimated between $200-300 million per year, yet increased drug resistance renders many compounds ineffective.
|
0.903 |
| 2004 — 2006 |
Zamecnik, Paul Charles |
R01Activity Code Description:
To support a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies. |
Oligonucleotides as Tools For Chemotherapy @ Massachusetts General Hospital
DESCRIPTION (provided by applicant): Completion of sequencing of the human and of bacterial genomes has made it possible to apply the principle of oligonucleotide hybridization competition to the inhibition of nefarious genic expression. We shall focus our efforts on three targets: l) M. tuberculosis, with its uniquely constructed mycocerosic outer cell wall; 2) Cystic Fibrosis, in which for our novel oligonucleotide insertion technique we must pin down the extent of insertion. Present estimates, as a result of over thousand sequencings, are that insertion occurs in 10-25 percent of delta508 mRNA molecules; 3) Huntington's Disease, requiring further studies to firm up our finding of inhibition of expression of Huntington protein in tissue cultures from patients with this disease, using derivatives of antisense oligonucleotides.
|
0.907 |